3,096 Shares in Novartis AG (NYSE:NVS) Acquired by TigerOak Management L.L.C.

TigerOak Management L.L.C. acquired a new position in shares of Novartis AG (NYSE:NVS) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 3,096 shares of the company’s stock, valued at approximately $301,000.

Other hedge funds have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Novartis by 128.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 528,682 shares of the company’s stock worth $51,554,000 after buying an additional 296,890 shares in the last quarter. World Investment Advisors LLC acquired a new stake in Novartis during the 3rd quarter worth approximately $30,063,000. Fisher Asset Management LLC lifted its holdings in Novartis by 15.7% during the 3rd quarter. Fisher Asset Management LLC now owns 1,706,009 shares of the company’s stock worth $196,225,000 after buying an additional 231,851 shares in the last quarter. Mediolanum International Funds Ltd acquired a new stake in Novartis during the 3rd quarter worth approximately $24,096,000. Finally, ABC Arbitrage SA acquired a new stake in Novartis during the 4th quarter worth approximately $19,795,000. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Novartis Price Performance

Shares of NYSE:NVS opened at $105.43 on Friday. The company’s fifty day moving average price is $100.70 and its 200 day moving average price is $108.30. Novartis AG has a 12 month low of $92.35 and a 12 month high of $120.92. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.04 and a quick ratio of 0.90. The firm has a market capitalization of $215.50 billion, a P/E ratio of 17.93, a P/E/G ratio of 1.70 and a beta of 0.58.

Novartis (NYSE:NVS) last announced its quarterly earnings results on Friday, January 31st. The company reported $1.98 EPS for the quarter, topping the consensus estimate of $1.80 by $0.18. Novartis had a net margin of 23.56% and a return on equity of 37.24%. As a group, sell-side analysts predict that Novartis AG will post 8.42 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on NVS shares. Morgan Stanley started coverage on shares of Novartis in a report on Wednesday. They set an “underweight” rating on the stock. BMO Capital Markets raised their price objective on shares of Novartis from $118.00 to $120.00 and gave the company a “market perform” rating in a report on Wednesday, October 30th. HSBC lowered shares of Novartis from a “hold” rating to a “reduce” rating in a report on Wednesday, December 4th. Erste Group Bank restated a “hold” rating on shares of Novartis in a report on Tuesday, November 19th. Finally, UBS Group restated a “neutral” rating on shares of Novartis in a report on Thursday. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $123.38.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.